Long-term alimentation for cancer patient

FIELD: food industry.

SUBSTANCE: invention is related to alimentary therapy. Proposed is a method providing for a cancer patient long-term alimentation and envisaging long-term administration of a nutritional product to the patient through a probe, the product containing a protein source providing for 14-25% of the product energy value and composed of whey (50% of energy value), glutamine (0.5% - 10% of energy value), leucine (0.8% - 3.5% of energy value), a carbohydrate source (20-55% of the product energy value) and a lipid source ( 25-40% of the product energy value). Optionally, the method envisages first administration of the above composition to a tumour cancer patient (through a probe) and then, upon normal metabolic status recovery - administration of a second composition for long-term alimentation that differs from the first composition in terms of formulation. Optionally, the method providing for a cancer patient long-term alimentation envisages administration of glutamine together with the above nutritional composition at least a week prior to commencement of the cancer therapy course.

EFFECT: invention enables to ensure well-balanced and efficient long-term through-probe alimentation of a cancer patient.

36 cl, 4 ex

 

The level of technology

The present invention relates to nutrition. More specifically, the present invention relates to therapeutic feeding.

In various diseases, strokes and complications, patients may be unable to obtain the necessary food by ingestion of food through the mouth, i.e. by eating food. Therefore known to provide therapeutic feeding enteral or parenteral means. Developed a number of different formulations for such healing power.

With regard to typical products for enteral nutrition, these products are designed for short-term use, usually from 10 to 24 days. In this regard, the products typically provide essential food components to provide the necessary nutrition in patients with acute pathologies during their stay in hospital. Although such products are suitable for short-term use, they do not necessarily applicable for long-term feeding of patients. Taking into account medical advances, leading to increased life expectancy and improved treatment of disease, a certain number of people could win if products are intended for long-term enteral nutrition.

Disclosure of inventions

According to the present invention, the provided methods and compositions for carrying out dolgovremennoi the power through the probe. More specifically, according to the present invention provided methods and compositions for long-term tube feeding for patients with cancer.

To this end, in one implementation a method of providing long-term nutrition of the cancer patient includes the steps of long-term administration through a feeding tube cancer patient at least once every day nutritional product comprising a protein source comprising 14-25% of the energy value of the product, the protein source comprises at least 50% of the energy value of serum, at least 0.5% of the energy value glutamine, at least 0.8% of the energy value leucine, a source of carbohydrates, comprising 20-55% of the energy value of the product, and a source of lipids, comprising 25-40% of the energy value of the product.

In one implementation glutamine is from 0.5 to 10% of the energy value of the product. Glutamine or its part can be placed in a separate container relative to the other components of the product. Glutamine may be in the form of free amino acids or may be in the form of rich in glutamine product, for example, the dipeptide. Glutamine can be included in alanyl-glutamine.

According to the way the source of protein may be native or partially hydrolyzed protein. The protein source can be 100% protein whey.

Source l the PIDA can provide 30-35% of the energy value of the product. The specific energy of the product is from 1.0 to 2.0 kcal. Additionally, the product may include a source of fiber.

In one implementation from 1.5 to 3.5% of the energy value of the product is leucine.

In one implementation of the method, the product contains enough vitamins and minerals to satisfy at least one official establishment selected from the group consisting of RDA (recommended daily intake) in U.S. RDA France and RDA Germany.

According to the implementation method, patients receive a second, different from the first product for enteral feeding, when reached normal metabolic status. In another implementation, the patient receives a second, different from the first product for enteral feeding before the diagnosis of cancer.

In another implementation of the present invention provides a method of conducting long-term enteral feeding of a patient with cancer, comprising the steps: a probe through a cancer patient during the inflammatory phase and lifting the weight of the first composition, comprising a protein source comprising 14-25% of the energy value of the product, the protein source comprises at least 50% of the energy value of serum, at least 0.5% of the energy value glutamine, at least 0.8% of energy is some value leucine, the source of carbohydrates, comprising 20-55% of the energy value of the product, and a source of lipids, comprising 25-40% of the energy value of the product, and probe the introduction of the cancer patient during the phase of normal metabolism of the second nutritional composition for long-term feeding, having a composition different from the first composition.

In implementing the method of the second composition for long-term power through the probe comprises per 100 kcal of product: protein source, a source of carbohydrates, a source of lipids, sodium 100-200 mg, potassium 25-250 mg, calcium 50 mg, phosphorus less than 150 mg of magnesium at least 15 mg, chloride of at least 100 mg, iron 0.4 to 1.5 mg, Zn 0.4 to 2.0 mg, copper 0.08 to 0.4 mg, fluoride 0-0,15 mg, chromium 2,0-10,0 mcg, molybdenum 2.0 to 14,0 mcg, selenium 3,0-9,0 mcg, manganese 0.1-0.4 mg, iodine 7,0-15,0 mcg, vitamin a 100-500 IU, vitamin D is 0.5 to 2.5 microgram, vitamin E of 1.5-4.0 mg, vitamin K more than 4.0 µg, vitamin C more than 4.0 mg, vitamin B1 than 0.06 mg, vitamin B2 more than 0.07 mg, vitamin B3 0.7 to 3.5 mg, vitamin B5 0.2 to 2.0 mg, vitamin B6 0.1 to 0.7 mg, vitamin B8 at least 1.0 microgram, vitamin B9 at least to 12.0 mcg and vitamin B12 0.1 to 1.0 μg.

In one implementation of the method glutamine is 0.5 to 10.0% of the energy value of the product. Glutamine or its part can be placed in the container separately from the other components of the product.

In an additional implementation of this izopet the deposits is provided a method of treating a cancer patient, including the stages of long-term administration at least once every day nutritional composition comprising a protein source comprising from 14 to 25% of the energy value of the product, where the protein source is at least 50% of the energy value of serum, a source of carbohydrates, which is from 20 to 55% of the energy value of the product, and the source of the lipids comprising from 25 to 40% of the energy value of the product, and to the treatment of cancer selected from the group consisting of chemotherapy and radiotherapy, the introduction together with the first nutrient mixture glutamine at the level of at least 0.5% of the total absorbed energy value.

In one implementation, the method may include the step of introducing the patient after treatment of the first nutritional composition without simultaneous administration of glutamine.

Additionally, in the implementation of the present invention provides a composition for carrying out long-term enteral feeding of a patient with cancer, comprising a protein source comprising from 14 to 25% of the energy value of the product, where the protein source is at least 50% of the energy value of serum, at least 0.5% of the energy value of glutamine, at least 0.8% of the energy value of leucine, a source of carbohydrates, which is from 20 to 55% of energy is some of the value of the product, and the source of the lipids comprising from 25 to 40% of the energy value of the product.

The advantage of the present invention is to provide improved products for enteral nutrition.

Another advantage of the present invention is to provide improved methods for enteral feeding.

Additionally, an advantage of the present invention is to provide compositions for enteral nutrition for conducting long-term enteral feeding of a patient with cancer.

Additionally, an advantage of the present invention is to provide methods of conducting long-term enteral enteral nutrition for patients with cancer.

Further properties and advantages described herein will become apparent from the following section.

The implementation of the invention

The present invention relates to therapeutic feeding. More specifically, the present invention relates to the provision of patient long-term enteral feeding. As used here, the term "long-term" means longer than one month (30 days). As used here, the term "probe" means the provision of the product to the patient through a tube for feeding, which is introduced into the digestive tract of the patient, such as nasogastric tube (probe) or subcutaneous endoscopic ha is trastamara tube (probe). The applicants also filed a patent application "Methods of ensuring long-term supply", the disclosure of which is included here by reference.

Products for long-term enteral feeding is created mainly for cancer patients. As used here, "cancer patient" refers to a patient who cannot obtain nutrition by normal or is malnourished and that hurts active cancer, i.e. not different abnormal metabolism. Active cancer can be cancer of the neck, head or digestive tract, or it may be a recurrence of cancer in a patient who was sick earlier and who was treated for cancer of the head, neck or digestive tract, with the result that he or she is unable to eat normally. As used here, the term "eat normally" means to receive at least the main part of the meal by eating, i.e. with the use of the mouth and without the use of any probe for feeding or parenteral probe.

The present invention provides nutritional compositions, which partly bring long-term benefit to the patients suffering from cancer, and especially during cancer treatment, such as chemotherapy or radiotherapy. These compositions provide advantages also in inflammatory and/or hypercatabolic States compared to standard products for enteral Pete the Oia. As used here, the term "standard products for enteral nutrition" refers to products that are not announced or are not designed specifically for long-term use. The variety of such products provided, for example, such companies as Nestle, Abbott, Novartis, Numico and Fresenius. Therefore, the product in part contains increased amounts of protein and too high in calories.

In part, the composition is enriched, preferably, ω3-polyunsaturated fatty acids (EPA and DHA). These fatty acids have good anti-inflammatory properties, especially for patients suffering from tumors. Preferably, the protein source is whey, especially proteins rich in cysteine, which has antioxidant properties and therefore anti-inflammatory action. In part, the antioxidant properties are provided by the synthesis of glutathione, which requires cysteine and glutamine as precursors.

The composition was created to be applied, at least at times, with added glutamine. Glutamine may be part of a composition or may be provided as a separate component. In this case glutamine can be provided in a separate compartment (in the form of a module). The compartment may contain powder or liquid with glutamine. In respect of glutamine and other modules can be referenced n is related patent application U.S. called "Nutrient modules", filed October 7, 2002, the disclosure of which is included here by reference. As an example, you can use the module with 30 g of glutamine together with 1500 ml of composition.

According to the implementation of the method according to the present invention, additional glutamine is administered to the patient before starting course of chemo - or radiotherapy, such as a week before, and is administered throughout the course and during the period of time after it, for example within two weeks after completion of treatment. During the administration of glutamine administered the composition together with glutamine or separately from it. In one implementation, once the acute inflammation has subsided, manifested, for example, in the form of mucositis, the introduction of glutamine can be stopped. Module with glutamine can be used to Supplement composition for treatment in the hospital or in Nebolsina environment, such as home care and nursing home.

Additionally, the composition of added L-leucine in such quantity that it ranged from 0.8 to 5% of the energy value of the composition. L-leucine is a potent stimulator of protein synthesis in the muscles.

According to the implementation of the present invention before diagnosis of the tumor with the necessity of treatment, if the patient requires enteral nutrition, specifically long-term enteral enteral nutrition, preferably PR is changing the supporting structure, as described in patent application U.S. under the title "Long-term enteral nutrition - maintaining", filed herewith, the disclosure of which is included here by reference. Similarly, nutrition support mixture can be resumed when the cancer is in remission and the patient reaches normal metabolic status.

Accordingly, the present invention provides long-term enteral nutrition for cancer patients, including the provision of two different compositions, one for a cancer patient with a tumor that needs treatment, and second to maintain patients after normal metabolic status restored. As used here, the term "maintaining patient" refers to an adult patient to 65 years, who can't eat normal way, but which has a normal metabolism (i.e. not suffering from metabolic disorders). For the sake of clarity, the applicants note that this invention discloses a composition for feeding a cancer patient, except for examples 3 and 4, as well as individual claims, which describes the composition to maintain the sick.

In one implementation, the composition according to the present invention can be applied to reduce the side effects of cancer and its treatment. Such side effects include cachexia, who agreed with cancer and mucositis, which can occur during treatment, such as chemotherapy and radiotherapy.

In one implementation, the composition (composition) includes the following components: a source of protein, providing 14-25% of the total energy value of the product, preferably 14 to 25% may be solid or partially hydrolyzed protein, of which at least 50% serum. In one implementation protein is made from 100% whey protein and a protein source, including the newly added amino acid, is 15-30% of the total energy value of the product, preferably 20-27%. In a preferred implementation, 3-7% of the energy value provided by glutamine and 1.5-3.5% of the energy value provided by leucine. By applying 100% whey protein is easily digestible protein with a relatively high content of cysteine. By adding to this mixture of leucine can meet increased demand in a given portion of the population.

The source of carbohydrates preferably includes 20-55% of the total energy value of the product. You can use any carbohydrate or mixture of carbohydrates. Examples include starch, maltodextrins, sucrose, and their mixture. In one implementation used 100% maltodextrin.

Additionally, a source of lipids is 25-40% of the total energy value of food the KTA. Preferably, 1.0 to 7% by weight of a source of lipids is eicosapentaenoic acid (EPA). By applying EPA can provide the necessary ratio of n3:n6, because these patients suffer from inflammation and oxidative stress. You can apply any appropriate mixture of food lipids. Such lipids include saturated fatty acids (SFA), monounsaturated fatty acids (MUFA), polyunsaturated fatty acids (PUFA) and triglycerides medium chain length (MCT). Preferably, the source of lipids is 30-35% of the total energy value of the product. It should be noted that preferably the specific energy of the composition is 1.0 to 2.0 kcal/ml

The present invention provides methods and products, optimized and/or improved for long-term use. In one implementation, these products are administered to the patient outside of the hospital accommodation. For example, you can enter products in the home for the elderly, kindergartens or other outpatient facilities, or even at home by the patient. Preferably, the foodstuff is placed in a plastic bag. There are a large variety of such bags, such as bags of 500 ml, 1000 ml and 1500 ml known in the art. It should be noted, however, that you can use any suitable container for accommodating food. In one implementation about the SPS created to provide the necessary power in 1500 ml / day, although the person skilled in the art will understand that changes are possible up to this amount.

Preferably, the products include the necessary nutrients to provide the full power of the patient on a long term basis. For this purpose, the products include, among other possible ingredients are proteins, carbohydrates, fats, vitamins and minerals. In one implementation, the products are mainly, if not completely correspond, at least, certain formal requirements. As used here, "formal requirements" means any recommendations from any of the following official documents: for the U.S., usually RDA United States, Germany, usually RDA Germany, France, usually RDA France. In one implementation of the food product meets at least one of the official request.

Examples, data illustrative purposes and not to limit the invention.

Examples 1 and 2 is designed for use from the moment of diagnosis to the time when the tumor is in remission.

As an example, and not limitation, in one implementation of the present invention one of the compositions described in examples 1 and 2, is administered to the patient in the period between diagnosis and restoration of normal metabolic status.

This product can be entered at least once a day. If necessary, glutamine can be provided in a separate module. Before diagnosis, if necessary, the patient can get stock to maintain given in examples 3 and 4. Similarly, after treatment is completed and the tumor is in remission, the patient receives a composition for maintaining shown in examples 3 and 4.

In another implementation of the method after the diagnosis of cancer patient injected with 1500 ml per day of one of the compositions of examples 1 and 2. At least one week before the course of treatment of a cancer patient injected with 30 g of glutamine from the module simultaneously with the introduction of the composition. Two weeks after completion of treatment, the addition of glutamine to stop and introduction composition continue if necessary.

It should be understood that various changes and modifications of the described preferred implementations described herein are obvious to a person skilled in the art. Such changes and modification can be done without leaving the region PR is tasani of the present invention and without diminishing put in it advantages. Thus understood that such changes and modifications are covered by the attached claims.

1. The way to ensure long-term food a cancer patient, introducing a cancer patient at least once a day long through the probe nutritional product, including:
source of protein, providing 14-25% of the energy value of the product, where the protein source is at least 50% of the energy value of serum,
for from 0.5 to 10% of the energy value of glutamine,
at from 0.8 to 3.5% of the energy value of leucine,
the source of carbohydrates, comprising 20-55% of the energy value of the product and
the source of the lipids constituting 25-40% of the energy value of the product.

2. The method according to claim 1, wherein the glutamine is 0.5 to 10.0% of the energy value of the product.

3. The method according to claim 1, characterized in that at least part of the glutamine before the introduction is located in the container separately from the other components of the product.

4. The method according to claim 1, characterized in that the source of protein is native or partially hydrolyzed protein.

5. The method according to claim 1, wherein the glutamine protein bound.

6. The method according to claim 1, characterized in that glutamine is a free amino acid.

7. The method according to claim 1, wherein the glutamine of uhodit composition of the dipeptide.

8. The method according to claim 1, characterized in that the source of protein is 100% whey protein.

9. The method according to claim 1, characterized in that 3 to 7% of the energy value of the product provided by glutamine.

10. The method according to claim 1, wherein from 1.5 to 3.5% of the energy value of the product provided by leucine.

11. The method according to claim 1, characterized in that the source of lipids provides from 30 to 35% of the energy value of the product.

12. The method according to claim 1, characterized in that the energy density of the product is between 1.0 and 2.0 kcal.

13. The method according to claim 1, wherein the product includes a source of fiber.

14. The method according to claim 1, characterized in that it further patient receives a second, different from the first product for enteral feeding after the restoration of normal metabolism.

15. The method according to claim 1, wherein the glutamine is included in alanyl-glutamine.

16. The way to ensure long-term enteral feeding of a patient with cancer, comprising the steps:
the probe through a cancer patient with a tumor that required treatment, the first composition comprising a protein source comprising 14-25% of the energy value of the product, and the source of protein is at least 50% of the energy value of serum, 0.5 to 10% of the energy value of glutamine, from 0.8 to 3.5% of the energy value is C leucine, the source of carbohydrates, comprising 20-55% of the energy value of the product and the source of the lipids constituting 25-40% of the energy value of the product and the probe through a cancer patient after restoration of normal metabolic status of the second composition for long-term power, which has a composition different from the composition of the first composition.

17. The method according to item 16, characterized in that the second composition for long-term power supply comprises per 100 kcal of the product:
the protein source,
the source of carbohydrates,
the source of lipids,
sodium 100-200 mg
potassium 25-250 mg
the more calcium 50 mg,
phosphorus less than 150 mg
magnesium is at least 15 mg,
chloride of at least 100 mg,
iron of 0.4-1.5 mg,
zinc 0,4-2,0 mg
copper 0.08 to 0.4 mg,
fluoride 0-0,15 mg,
chrome 2,0-10,0 mg,
molybdenum 2.0 to 14,0 mcg,
selenium 3,0-9,0 mcg,
manganese 0.1-0.4 mg,
iodine 7,0-15,0 mcg,
vitamin a 100-500 IU,
vitamin D is 0.5 to 2.5 mg,
vitamin E 1.5 to 4.0 mg,
vitamin K is more than 4.0 µg,
vitamin C greater than 4.0 mg
vitamin B1 than 0.06 mg,
vitamin B2 is more than 0.07 mg
vitamin B3 0.7 to 3.5 mg,
vitamin B5 0.2 to 2.0 mg,
vitamin B6 0.1 to 0.7 mg,
vitamin B8 at least 1.0 μg,
vitamin B9 at least to 12.0 µg,
vitamin B12 0.1 to 1.0 μg.

18. The method according to item 16, wherein the glutamine is from 0.5 to 10.0% of the energy value of the product.

19. The method according to item 16, wherein the glutamine room is EN in the container separately from the other components of the product.

20. The method according to item 16, wherein the source of protein is native or partially hydrolyzed protein.

21. The method according to item 16, wherein the source of protein is made from 100% whey protein.

22. The method according to item 16, wherein from 3 to 7% of the energy value of the product provides the glutamine.

23. The method according to item 16, wherein from 1.5 to 3.5% of the energy value of the product provides a leucine.

24. The method according to item 16, characterized in that the energy density of the product is between 1.0 and 2.0 kcal.

25. The method according to item 16, wherein the product includes a source of fiber.

26. The way to ensure long-term enteral feeding of a patient with cancer, comprising the steps:
introduction at least once a day nutritional composition for long-term nutrition, including protein source comprising 14-25% of the energy value of the product, and the source of protein is at least 50% of the energy value of serum, a source of carbohydrates, comprising 20-55% of the energy value of the product and the source of the lipids constituting 25-40% of the energy value of the product and
the introduction of at least one week before the start of treatment of cancer glutamine together with a nutrient composition.

27. Composition to provide the cancer patient long-term supply through the probe include the nd:
a protein source comprising 14-25% of the energy value of the product, and the source of protein is at least 50% of the energy value of serum, 0.5 to 10% of the energy value of glutamine, from 0.8 to 3.5% of the energy value of leucine, a source of carbohydrates, comprising 20-55% of the energy value of the product and the source of the lipids constituting 25-40% of the energy value of the product.

28. The composition according to item 27, wherein the glutamine is from 0.5 to 10.0% of the energy value of the product.

29. The composition according to item 27, wherein the glutamine is placed in the container separately from the other components of the product.

30. The composition according to item 27, wherein from 14 to 25% of the energy value protein source is native or partially hydrolyzed protein.

31. The composition according to item 27, wherein the source of protein is made from 100% whey protein.

32. The composition according to item 27, wherein the glutamine is from 3 to 7% of the energy value of the product.

33. The composition according to item 27, wherein the leucine is from 1.5 to 3.5% of the energy value of the product.

34. The composition according to item 27, wherein the source of lipids provides from 30 to 35% of the energy value of the product.

35. The composition according to item 27, wherein the specific energy product finds the I between 1.0 and 2.0 kcal.

36. The composition according to item 27, wherein the product includes a source of fiber.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to new compounds of formula (I) or to their salts:

,

where: R1 or R2, independently represents a group consisting of R1, R2, N and/or O selected from the groups:

,

Z1 represents hydrogen or hydroxyl; Z2 represents hydrogen or hydroxyl; Z3 represents C6-C10aryl; Z4 represents C1-C6alkoxy. The invention also refers to a method for producing the compounds according to any of claims 1-4, as well as to application of the compounds.

EFFECT: preparation of new biologically active compounds which exhibit anticancer activity.

12 cl, 10 ex, 3 tbl, 2 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to compounds (la) of formula applied as tyrosine kinase c-Met inhibitors. , where: LA is selected from ,

or ; RA is selected from:

or each RA2 and RA6 represents hydrogen; RA3 represents RAr; or RA3, RA4 and carbon atoms whereto attached form 6-members aryl, optionally substituted, in the amount up to 4 by independent groups RAr, or a 5-6-members heterocyclyl or heteroaryl ring containing at least one O, N or S atom; R represents -OH; RA5 represents hydrogen or RAr; LB represents a covalent bond or -N(R*)-; RB represents halogen, NH2 or C1-8aliphatic group, optionally substituted by R; a 6-10-members aryl ring; a 3-7-members carbocyclyl ring, a 5-10-members heteroaryl ring containing 1-4 heteroatoms independently selected from nitrogen, oxygen and sulphur atoms, where each said aryl or heteroaryl ring is optionally substituted, in the amount up to five by independent groups RAr; R represents halogen, -R°, -SR°, Ph, optionally substituted R° or -C(O)OR°; each RAr is independently selected from halogen, -R°, -OR°, -SR°, Ph, optionally substituted in the amount up to five by independent groups -R°, -CN, -N(R°)2 or -C(O)OR°; or two adjacent groups RAr taken together, represent 1,2-methylenedixy or 1,2-ethylenedixy; each R* represents hydrogen; and each R° represents independently hydrogen, an optionally substituted C1-6aliphatic radical or an unsubstituted 5-6-members heteroaryl or heterocyclic ring containing 1-3 heteroatoms independently selected from nitrogen, oxygen and sulphur atoms.

EFFECT: invention refers to pharmaceutically acceptable compositions containing the compounds under the invention, and methods of application of the compositions in treatment of various proliferative disorders.

10 cl, 4 tbl, 548 ex, 9 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: there is described new macrocyclic compound of general formula 1-c:

and its pharmaceutically acceptable acid or base addition salts or its stereoisomers (the radical values are presented in the patent claim).

EFFECT: producing the compounds which are hepatitis type C virus inhibitors and can find application in medicine.

9 cl, 1 tbl, 95 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to a new acid dihydrogenphosphate of 2-(3-{6-[2-(2,4-dichlorophenyl)ethylamino]-2-methoxypyrimidine-4-yl}phenyl)-2-methylpropionic acid of formula optionally in a crystalline form exhibiting cAMP inhibitor properties. Also, the invention refers to a pharmaceutical composition.

EFFECT: compound can find application for treating the diseases associated with cell expression of prostaglandin D2 in such diseases, as allergic rhinitis, bronchial asthma, allergic conjunctivitis, etc.

3 cl, 12 dwg, 1 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of formula which exhibits an inhibiting action on protein kinases A and B. In the compounds of formula (I), A represents a saturated hydrocarbon binding group containing 1 to 7 carbon atom where the binding group includes a chain of the maximum length 5 atoms located between R1 and NR2R3, and a chain of the maximum length 4 atoms located between E and NR2R3 where one of carbon atoms in the binding group can be optionally substituted by an oxygen or nitrogen atom; and where the carbon atoms of the binding group A can optionally have one or more substitutes selected from oxo, fluorine and hydroxy provided the hydroxy group if any is not located on a carbon α-atom in relation to the NR2R3 group and provided the oxo group if any is located on the carbon α-atom in relation to the NR2R3; E represents a phenyl or pyridine group; R1 represents a C6-10aryl or pyridyl group which is not substituted or substituted with 1 or 2 substitutes specified in the patent claim; and R2, R3, R4 and R5 have the values specified in the points of the patent claim.

EFFECT: invention refers to a pharmaceutical composition containing said compounds, to methods of making the compounds and their application as cancer drugs.

29 cl, 1 tbl, 108 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of general formula

where there are R3/R3', R4/R4' and R5/R5' where at least one of either R4/R4' or R5/R5' always represents a fluorine atom, and the other radical values are disclosed in the description.

EFFECT: making the compounds which are γ-secretase inhibitors, and can be effective in treating Alzheimer's disease or advanced cancers, including but not limited to carcinoma of uterine cervix and breast carcinoma and malignant tumours of hematopoietic system.

15 cl, 3 tbl, 18 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to oncology and deals with application of antimicrobial protein of human platelets as anti-tumour medication.

EFFECT: invention insures extension of arsenal of anti-tumour medications for treatment of malignant neoplasms.

1 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of pharmaceutics and medicine and deals with anticancer pharmaceutical composition or combination for prevention cancer of lungs or cancer of kidney, which contains as active ingredients medication, which is produced from gefitinib, erlotinib and soraphenib, and dihydrochloride 5-(4-(6-(4-amino-3,5-dimetylphenoxy)-1-metyl-1H-benzimidazol-2-ilmethoxy)benzyl)thiazolidine-2,4-dione.

EFFECT: invention insures increased efficiency of treatment.

16 cl, 5 dwg, 3 tbl, 18 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to oncology and can be used for treatment of locally spread resectable esophageal cancer. Method includes radical surgery, polychemotherapy and radiotherapy. Before operation 2 courses of polychemotherapy are carried out in accordance with the scheme: cysplatin 50 mg/m2 1,8 day, gemcitabine -800 mg/m2 intravenously drop-by-drop during half-hour infusion - 2, 9 days with 3-week long interval between courses. After that, surgical intervention in radical volume with two-zonal 2F lymphodissection, with carrying out IORT in single dose 10 Gy onto the bed of removed tumour and ways of regional metastasis. In post-operational period additionally course of DGT is carried out on cervical, supraclavicular zones in TFD -40 Gy.

EFFECT: application of invention makes it possible to increase efficiency of combined treatment due to prevention of tumour process progression and distant metastasis and reduction of number of post-operational complications.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to compounds, which bind with BIR domains of IAP, namely with BIR2 and BIR3 domains. Compounds are represented by formula I It is known that apoptotic pathways play critical role in development of cancer, autoimmune disorders and neurodegenerative diseases. Also described is method of obtaining formula I compounds and their pharmaceutical compositions, as well as intermediate compounds for obtaining formula I compounds.

EFFECT: obtaining pharmaceutical compositions for changing apoptotic reactions in cells, which can contribute to treatment of proliferative disorders.

45 cl, 1 dwg, 11 tbl, 23 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to obstetrics and gynecology, and can be used for complex treatment of iron-deficiency anemia in pregnant women. For this purpose traditional pharmacotherapy with iron-containing medication is administered. Additionally administered is "Yantar-energovit" in dose 0.5 g 3 times per day after meal for 3-4 weeks. After that, it is administered in dose 0.5 g 1 time per day for 3 weeks. Courses of additional intake of "Yantar-energovit" are alternated till fetus delivery, depending on degree of iron-deficiency anemia severity.

EFFECT: method ensures increase of treatment efficiency, reduction of number of obstetrical complications during pregnancy and labour and, thus, prevent possible perinatal loss.

2 tbl

FIELD: medicine.

SUBSTANCE: claimed is application of adapalene in obtaining medication for local application for administering to patients in order to support their biological response in treatment of common acne, where the scheme includes introduction of therapeutically effective amount of adapalene, at least, one time per two days for, at least, 6 months, where medication for local application contains from 0.25% to 0.5% of adapalene in weight; or introduction of therapeutically effective amount of adapalene, at least, one time per two days for, at least, 6 months (versions). Claimed application ensures efficient treatment of common acne in long-term treatment without evidence of systemic toxicity. Expected signs and symptoms of skin irritation - mainly mild or temperate and transient - are observed.

EFFECT: elaboration of efficient medication for acne treatment.

11 cl, 2 dwg, 17 tbl

FIELD: medicine.

SUBSTANCE: invention relates to field of veterinary medicine. Method includes per oral application of sodium acetate in dose 275-440 g 2 times per day, preliminarily solving it in 2 l of warm water.

EFFECT: method makes it possible to reduce terms of animal recovery.

1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine and is intended for treatment of bile passages dysfunction in children with acute intestinal infections. Used is medication Mebeverine, which is administered per os for one month after acute intestinal infection. Day dose of mebeverine constitutes for children from 3 to 4 years of age - 75 mg per day, for children from 4 to 8 years old - 150 mg per day, for children from 9 to 10 years - 300 mg per day, for children older than 10 years - 450 mg per day.

EFFECT: method makes it possible to normalise indices of bile bladder function and prevent possibilities of formation of its post-infection motility disorders.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: acidic concentrated solution is supplied into apparatus "Artificial kidney", which in automated mode performs its dissolution in ratio, specified by apparatus programme, and mixing with bicarbonate component. Obtained dialysing solution contains the following components, in mmol/l: sodium chloride NaCl 137.3-140.3, calcium chloride CaCl2·2H2O 1.2-1.75, magnesium chloride MgCl2·6H2O 0.5-1.0, potassium chloride KCl 0.3-4.0, sodium diacetate 0-6.0, succinic acid 0.44 or 0.88 or 1.0, glucose, g/l 0-5.0, sodium bicarbonate NaHCO3 32.0.

EFFECT: elaboration of efficient method of obtaining hemodialysing solution for bicarbonate hemodialysis for treatment of patients with acute and chronic renal failure

6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to chemical-pharmaceutical industry. Pharmaceutical compositions including, at least, one compound of formula where -X- represents, for instance, group of formula and Y represents, for instance, group of formula or its pharmaceutically acceptable salts, esters or amides, or pro-drugs and pharmaceutically acceptable carrier, which is acceptable in therapy, can be applied for modulation in vitro and in vivo processes of binding, mediated by binding of E-, P- or L- selectin.

EFFECT: obtaining novel floroglucin derivatives.

9 cl, 10 ex, 3 tbl

FIELD: medicine.

SUBSTANCE: invention refers to drugs, and concerns an application of an LXR agonist for preparing a drug effective for treatment and/or prevention of type I diabetes and a method of increasing primary pancreatic islet viability ex vivo wherein said pancreatic islets contact with the LXR agonist.

EFFECT: extended range of products for type I diabetes treatment.

13 cl, 8 dwg, 8 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a chrysophanol conjugate or its derivative, characterised by general formula (I), in which R1-R8 is a group selected from -H, -OH, -OCH3, -CH3, provided that not less than two groups from R1-R8 denote -H or provided that one or two of groups R2, R3, R6 and R7 are a -COOH group, M is a nitrogen organic base selected from a group comprising chitosamin, glucosamin, or a basic amino acid selected from a group comprising arginine, lysine, carnitine, and group M is bonded to the chrysophanol part in the conjugate.

EFFECT: invention relates to use of the conjugate as a medicinal agent for preventing or treating diabetic nephropathy, osteoarthritis, rheumatic or rheumatoid arthritis, intestinal adhesion, intestinal peristalsis restoration, and a medicinal agent based on the conjugate.

8 cl, 4 dwg, 57 ex, 18 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to a chrysophanol conjugate or its derivative, characterised by general formula (I), in which R1-R8 is a group selected from -H, -OH, -OCH3, -CH3, provided that not less than two groups from R1-R8 denote -H or provided that one or two of groups R2, R3, R6 and R7 are a -COOH group, M is a nitrogen organic base selected from a group comprising chitosamin, glucosamin, or a basic amino acid selected from a group comprising arginine, lysine, carnitine, and group M is bonded to the chrysophanol part in the conjugate.

EFFECT: invention relates to use of the conjugate as a medicinal agent for preventing or treating diabetic nephropathy, osteoarthritis, rheumatic or rheumatoid arthritis, intestinal adhesion, intestinal peristalsis restoration, and a medicinal agent based on the conjugate.

8 cl, 4 dwg, 57 ex, 18 tbl

FIELD: medicine.

SUBSTANCE: claimed is medication for treatment of blood loss, consisting of complex representing combination of insulin 14 U, glucose solution 10% - 400 ml, sodium adenosine triphosphate 1% - 1 ml, panangin 10 ml, strophanthin acetate 0.05% - 0.25 ml, ascorbic acid 5% - 2 ml, riboxin 10ml, analgin 25% - 1 ml, polyglucinum 6% -400 ml.

EFFECT: medication in express-mode simultaneously produces rehabilitating action on all factors of blood loss etiopathogenesis, including elimination of acidosis, stress and pain syndrome.

1 ex

Antioxidant complex // 2419362

FIELD: food industry.

SUBSTANCE: invention is related to food industry, in particular - to production of specialised products based on natural raw materials that may be used for alimentation of sportsmen as well as persons leading an active lifestyle. The antioxidant complex contains dihydroquercetin, L-carnozine, zinc citrate, selenopyran and vitamins A, C, E at a certain ratio. The invention enables reliable protection against multiple effects of oxidation and free radical impact.

EFFECT: maximally efficient dosage of the active components and absolutely accurately selected proportion of antioxidants in the formulated complex composition enable manifold intensification of the organism protective function and a significant cascade antioxidant action.

4 cl

Up!